{"id":45882,"date":"2025-11-05T15:37:06","date_gmt":"2025-11-05T07:37:06","guid":{"rendered":"https:\/\/flcube.com\/?p=45882"},"modified":"2025-11-05T15:37:07","modified_gmt":"2025-11-05T07:37:07","slug":"msd-secures-full-global-rights-to-mk%e2%80%918690-after-150-million-settlement-with-falk-pharma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45882","title":{"rendered":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma"},"content":{"rendered":"\n<p><strong>Merck Sharp &amp; Dohme Inc. (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>)<\/strong>, through its 2023 acquisition of <strong>Prometheus BioSciences<\/strong>, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with <strong>Dr.\u202fFalk Pharma GmbH (Falk)<\/strong> for the anti\u2011CD30 ligand monoclonal antibody <strong>MK\u20118690<\/strong> (formerly PRA\u2011052). Under the settlement, MSD now holds <strong>sole responsibility for the entire MK\u20118690 development program<\/strong> and will assume full commercial rights worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>MSD (via Prometheus BioSciences) &amp; Falk Pharma<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>MK\u20118690 (anti\u2011CD30L monoclonal antibody) \u2013 early\u2011stage clinical candidate<\/td><\/tr><tr><td><strong>Original 2020 Agreement<\/strong><\/td><td>Joint development; Falk covered 25\u202f% of costs and held exclusive rights in Europe, Australia &amp; New\u202fZealand. Prometheus retained U.S. and \u201crest\u2011of\u2011world\u201d rights.<\/td><\/tr><tr><td><strong>Current Settlement<\/strong><\/td><td>Full global rights transferred to MSD; Falk receives <strong>US$150\u202fmillion<\/strong> upfront plus potential milestone payment and royalty stream on sales in its former territories.<\/td><\/tr><tr><td><strong>Milestone\/Royalty<\/strong><\/td><td>Specific milestone amount undisclosed; royalty rate to be negotiated per territory.<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>Agreement executed 5\u202fNov\u202f2025; rights transfer effective immediately.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-background-prometheus-acquisition\">Background \u2013 Prometheus Acquisition<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2023<\/strong> \u2013 MSD acquired <strong>Prometheus BioSciences<\/strong> for its pipeline, including the CD30L antibody <strong>MK\u20118690<\/strong> and the TL1A antibody.<\/li>\n\n\n\n<li><strong>MK\u20118690<\/strong> \u2013 Investigational monoclonal antibody targeting the CD30 ligand, currently in <strong>Phase\u202f1\/2<\/strong> safety and dose\u2011escalation studies for hematologic malignancies.<\/li>\n\n\n\n<li><strong>Strategic Fit<\/strong> \u2013 The drug aligns with MSD\u2019s oncology portfolio and its push into next\u2011generation immuno\u2011oncology therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-implications\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Cash Outlay<\/strong> \u2013 The <strong>US$150\u202fmillion<\/strong> upfront payment represents a modest cash commitment relative to the estimated <strong>$1\u2011$2\u202fbillion<\/strong> development cost required to bring MK\u20118690 to market.<\/li>\n\n\n\n<li><strong>Risk Consolidation<\/strong> \u2013 By assuming 100\u202f% of development risk, MSD can streamline trial design, regulatory filing, and commercial strategy without cross\u2011licensing constraints.<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong> \u2013 CD30L is a validated target in <strong>Hodgkin lymphoma, anaplastic large\u2011cell lymphoma, and emerging solid\u2011tumor indications<\/strong>. Successful development could add <strong>$3\u2011$5\u202fbillion<\/strong> in peak sales potential.<\/li>\n\n\n\n<li><strong>Royalty Income for Falk<\/strong> \u2013 Falk retains a royalty stream on sales in Europe, Australia and New\u202fZealand, providing a long\u2011term upside without further capital exposure.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook-amp-next-steps\">Outlook &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Program<\/strong> \u2013 MSD plans to accelerate the Phase\u202f1\/2 trial, targeting a <strong>mid\u20112026<\/strong> read\u2011out for safety and preliminary efficacy.<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong> \u2013 Early engagement with the <strong>FDA<\/strong>, <strong>EMA<\/strong>, and <strong>PMDA<\/strong> to explore accelerated pathways (e.g., Fast Track, PRIME).<\/li>\n\n\n\n<li><strong>Commercial Planning<\/strong> \u2013 Integration of MK\u20118690 into MSD\u2019s global oncology sales force and potential partnership with regional biotech firms for late\u2011stage development.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the development timeline, regulatory strategy, and commercial potential of MK\u20118690. Actual results may differ due to clinical outcomes, regulatory decisions, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Sharp &amp; Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45883,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[2675,176,903,2453],"class_list":["post-45882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-prometheus-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck Sharp &amp; Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with Dr.\u202fFalk Pharma GmbH (Falk) for the anti\u2011CD30 ligand monoclonal antibody MK\u20118690 (formerly PRA\u2011052). Under the settlement, MSD now holds sole responsibility for the entire MK\u20118690 development program and will assume full commercial rights worldwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45882\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma\" \/>\n<meta property=\"og:description\" content=\"Merck Sharp &amp; Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with Dr.\u202fFalk Pharma GmbH (Falk) for the anti\u2011CD30 ligand monoclonal antibody MK\u20118690 (formerly PRA\u2011052). Under the settlement, MSD now holds sole responsibility for the entire MK\u20118690 development program and will assume full commercial rights worldwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45882\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T07:37:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T07:37:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma\",\"datePublished\":\"2025-11-05T07:37:06+00:00\",\"dateModified\":\"2025-11-05T07:37:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506.webp\",\"keywords\":[\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Prometheus Biosciences\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45882#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45882\",\"name\":\"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506.webp\",\"datePublished\":\"2025-11-05T07:37:06+00:00\",\"dateModified\":\"2025-11-05T07:37:07+00:00\",\"description\":\"Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with Dr.\u202fFalk Pharma GmbH (Falk) for the anti\u2011CD30 ligand monoclonal antibody MK\u20118690 (formerly PRA\u2011052). Under the settlement, MSD now holds sole responsibility for the entire MK\u20118690 development program and will assume full commercial rights worldwide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45882\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0506.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45882#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma - Insight, China&#039;s Pharmaceutical Industry","description":"Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with Dr.\u202fFalk Pharma GmbH (Falk) for the anti\u2011CD30 ligand monoclonal antibody MK\u20118690 (formerly PRA\u2011052). Under the settlement, MSD now holds sole responsibility for the entire MK\u20118690 development program and will assume full commercial rights worldwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45882","og_locale":"en_US","og_type":"article","og_title":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma","og_description":"Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with Dr.\u202fFalk Pharma GmbH (Falk) for the anti\u2011CD30 ligand monoclonal antibody MK\u20118690 (formerly PRA\u2011052). Under the settlement, MSD now holds sole responsibility for the entire MK\u20118690 development program and will assume full commercial rights worldwide.","og_url":"https:\/\/flcube.com\/?p=45882","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T07:37:06+00:00","article_modified_time":"2025-11-05T07:37:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45882#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45882"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma","datePublished":"2025-11-05T07:37:06+00:00","dateModified":"2025-11-05T07:37:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45882"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp","keywords":["Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Prometheus Biosciences"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45882#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45882","url":"https:\/\/flcube.com\/?p=45882","name":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45882#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp","datePublished":"2025-11-05T07:37:06+00:00","dateModified":"2025-11-05T07:37:07+00:00","description":"Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences, announced today that it has terminated the co\u2011development and co\u2011commercialization agreement with Dr.\u202fFalk Pharma GmbH (Falk) for the anti\u2011CD30 ligand monoclonal antibody MK\u20118690 (formerly PRA\u2011052). Under the settlement, MSD now holds sole responsibility for the entire MK\u20118690 development program and will assume full commercial rights worldwide.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45882#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45882"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45882#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp","width":1080,"height":608,"caption":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45882#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD Secures Full Global Rights to MK\u20118690 After $150\u202fMillion Settlement with Falk Pharma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45882"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45882\/revisions"}],"predecessor-version":[{"id":45884,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45882\/revisions\/45884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45883"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}